Navigation Links
Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
Date:12/9/2008

progression has not yet been established for this study.

According to Dr. Vij, "Single-agent carfilzomib has shown impressive and durable activity, notably among patients who have failed transplantation and have not yet received treatment with a proteasome inhibitor. The emerging safety profile makes this an attractive option in patients who have pre-existing neuropathy. Continued evaluation of carfilzomib in less heavily pre-treated patients is warranted given these promising findings."

Carfilzomib was generally well tolerated among relapsed patients and toxicities were manageable. The most common adverse events were fatigue, anemia and neutropenia. Two cases of tumor lysis syndrome were observed among bortezomib-naive patients, and with additional monitoring and management guidelines no further events have been reported. No treatment-emergent Grade 3 or 4 peripheral neuropathy was reported in this study.

Dr. Vij presented these interim data from a study of relapsed patients in a presentation titled Initial Results of PX-171-004, an Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma (MM) (Abstract #865).

"We are encouraged by the data that show that carfilzomib is active and has been successful in providing durable responses in patients who have relapsed or who do not respond to currently available treatment options," said Lori A. Kunkel, M.D., Proteolix's Chief Medical Officer. "We believe carfilzomib may have broad application in the treatment of hematologic malignancies and solid tumors."

Supporting Preclinical Data

In addition to the two oral presentations of Phase 2 clinical data, Proteolix scientists presented results of preclinical studies that further characterize the mechanism and safety profile of carfilzomib. These data were presented on Sunday, December 7 in two poster presentations: Non-Proteasom
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Massachusetts og SHENZHEN ... Tech Solutions Co., LTD, (BGI Tech), et datterselskab ... lancering af en ny human whole exome-sekvenseringstjeneste baseret ... Complete Genomics, højt anset i branchen for at ... højfølsom registrering af alle typer varianter, blev købt ...
(Date:7/22/2014)... Switzerland (PRWEB) July 22, 2014 ... are becoming an increasingly common sight. The rapid ... they are now well- established as a core ... low maintenance has made them the gas analyzer ... locations and conditions encountered in some processes have ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Holomic ... with the debut of its fluorescent immunoassay reader, ... Chemistry (AACC) meeting in Chicago, July 28-31, 2014. ... top versions, the HRDR-300 is a highly sensitive, ... to analyze fluorescent lateral flow immunoassays with high ...
(Date:7/21/2014)... 21, 2014 Lawrence Livermore ... Board (WIB) and Las Positas College (LPC) recently ... education and hands-on training for veterans, officials recently ... at Las Positas is designed to help ... engineering technician careers, and establishes a pipeline of ...
Breaking Biology Technology:BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3
... on August 21 and Roth Capital,s 2007 New York ... ... Strategic Diagnostics,Inc. (Nasdaq: SDIX ) -- a leading ... water, agricultural, environmental and,life science applications, announced today that its ...
... BioMaxx Systems Inc. (Other,OTC: BMXSF), is pleased ... with,Alcofuel Technologies Ltd., for the provision of the ... to the engagement,letter, Alcofuel Technologies has agreed, subject ... to design and manufacture a small,scale ethanol micro-refinery ...
... Pharmaceuticals,Inc. (Amex: ANX ) a biopharmaceutical ... product candidates for the treatment,of cancer and ... Food and,Drug Administration (FDA) has granted fast ... is currently being investigated in a,pivotal Phase ...
Cached Biology Technology:Strategic Diagnostics to Present at Two Upcoming Investor Conferences 2Strategic Diagnostics to Present at Two Upcoming Investor Conferences 3Strategic Diagnostics to Present at Two Upcoming Investor Conferences 4Strategic Diagnostics to Present at Two Upcoming Investor Conferences 5BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3
(Date:7/22/2014)... emerging as a world-famous vacation spot with natural tourism resources, ... island. The Korea Institute of Geoscience and Mineral Resources (KIGAM) ... recent volcanic eruption was evident 5,000 years ago. That is ... lava spewed out of a volcano 5,000 years ago in ... one the whole peninsula. , The research team led by ...
(Date:7/22/2014)... is known about the the genus of planthopper known ... new one was recently discovered in the southern part ... Jaen. A description of it appears in the open-access ... ). , The new species, Conosimus baenai , ... for his contributions to the taxonomy of Iberian Hemiptera. ...
(Date:7/21/2014)... Their scruffy beards weren,t ironic, but there are reasons ... the Ice Age. , According to research from the ... liked living in Greater Cincinnati long before it was ... age. A study led by Brooke Crowley, an assistant ... enjoyed the area so much they likely were year-round ...
Breaking Biology News(10 mins):Jeju Island is a live volcano 2Mammoth and mastodon behavior was less roam, more stay at home 2Mammoth and mastodon behavior was less roam, more stay at home 3
... scientist from The Scripps Research Institute has identified a new ... formation. The molecule could become a target for the development ... as Hemophilia A. The findings, from a study by ... a recent edition of Journal of Biological Chemistry . ...
... Avantra Biosciences (Avantra) today announced the selection ... test site for Avantra,s new biomarker quantitation platform. ... has created an automated multiplex immunoassay system to ... patient characteristics, and drug responses. The new Q400 ...
... - A Purdue University scientist has found genetic evidence of ... finding he believes could one day be used to help ... Salt, a professor of horticulture, noticed several years ago that ... tolerate higher levels of sodium had come from coastal areas. ...
Cached Biology News:Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 2Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 3Avantra Biosciences teams with TGen Drug Development to assist pharma 2Plants can adapt genetically to survive harsh environments 2